Last 46 quarters of trend data · Healthcare · Medical - Instruments & Supplies
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -49.09 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | 9999.00 | 1105.37 | 912.45 | 876.27 | 3467.19 | — | — | — | — | — | — | — | — | — | — | — | — | 45.46 | 81.40 | 130.01 | 278.58 |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/B Ratio | 44.30 | 19.29 | 22.08 | 11.47 | 12.87 | 9.72 | 9.12 | 8.85 | 13.54 | 23.73 | 13.24 | 15.19 | 4.24 | 5.29 | — | — | 13.81 | 2.06 | 6.95 | 12.30 | 13.50 |
| — | +98.5% | +142.1% | +29.6% | -4.9% | -59.0% | -31.1% | -41.7% | +218.9% | +348.5% | — | — | -69.3% | +157.1% | — | — | +2.3% | -71.7% | -77.0% | -53.5% | +48.4% | |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | -360.0% | 37.1% | 7.7% | -96.6% | -224.4% | — | — | — | — | — | — | — | — | — | — | 14444.4% | — | -407.2% | -104.7% | -47.0% | -26.7% |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | +30808.1% | — | — | — | — | — | |
| Operating Margin | -21982.6% | -5823.0% | -4775.6% | -6914.0% | -23682.6% | — | — | — | — | — | — | — | — | — | — | 97166.7% | — | -5288.3% | -3890.3% | -1825.8% | -2486.6% |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | +5421.8% | — | — | — | — | — | |
| Net Margin | -20794.6% | -5681.3% | -4633.7% | -6603.4% | -22540.7% | — | — | — | — | — | — | — | — | — | — | 102188.9% | — | -5281.5% | -3890.3% | -1826.5% | -2488.2% |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | +5694.7% | — | — | — | — | — |
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -74.4% | -29.7% | -25.3% | -20.1% | -19.7% | -17.2% | -14.4% | -20.0% | -23.9% | -36.0% | -25.1% | -24.7% | -18.8% | -39.8% | — | -466.7% | -121.9% | -63.3% | -61.2% | -37.1% | -26.7% |
| — | -73.0% | -75.7% | -0.6% | +17.7% | +52.2% | +42.7% | +19.2% | -27.4% | +9.5% | — | +94.7% | +84.6% | +37.2% | — | -1157.6% | -357.1% | -65.6% | +29.0% | +25.0% | +22.4% | |
| ROA | -63.7% | -25.0% | -20.9% | -17.0% | -16.9% | -15.1% | -12.6% | -17.2% | -19.0% | -25.4% | -18.7% | -19.1% | -15.0% | -13.7% | -13.2% | -11.1% | -28.1% | -34.9% | -36.8% | -25.4% | -19.4% |
| — | -65.5% | -65.5% | +1.0% | +10.9% | +40.5% | +32.5% | +9.9% | -26.5% | -85.9% | -41.4% | -71.6% | +46.6% | +60.9% | +64.1% | +56.2% | -45.0% | -83.1% | -20.4% | +16.0% | +18.7% | |
| ROIC | -876.1% | -387.4% | -228.2% | -213.6% | -259.9% | -215.2% | -200.9% | -214.2% | -114.5% | -89.2% | -81.9% | -92.7% | -75.0% | -69.0% | -61.2% | -52.6% | -86.0% | -55.6% | -69.9% | -64.6% | -50.1% |
| — | -80.0% | -13.6% | +0.3% | -126.9% | -141.2% | -145.3% | -131.1% | -52.8% | -29.3% | -33.9% | -76.2% | +12.9% | -24.1% | +12.4% | +18.5% | -71.5% | +4.6% | +12.8% | -84.2% | -37.5% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.09 | 0.07 | 0.11 | 0.09 | 0.09 | 0.08 | 0.07 | 0.08 | 0.11 | 0.32 | 0.25 | 0.21 | 0.18 | 0.16 | — | — | 12.17 | 0.45 | 0.51 | 0.32 | 0.25 |
| — | -13.7% | +49.0% | +20.5% | -19.5% | -75.4% | -70.5% | -62.4% | -41.2% | +101.6% | — | — | -98.5% | -64.4% | — | — | +4676.4% | +106.7% | -80.1% | -36.5% | -27.2% | |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 10.53 | 9.63 | 7.26 | 10.53 | 10.02 | 12.05 | 15.58 | 11.88 | 11.93 | 4.57 | 7.06 | 6.76 | 9.50 | 10.68 | 7.86 | 10.39 | 10.17 | 3.14 | 2.49 | 4.30 | 5.17 |
| — | -20.1% | -53.4% | -11.4% | -16.0% | +163.7% | +120.8% | +75.8% | +25.5% | -57.2% | -10.2% | -35.0% | -6.5% | +240.4% | +215.8% | +141.7% | +96.7% | -50.0% | -65.8% | +46.0% | +2.3% | |
| Quick Ratio | 10.51 | 9.61 | 7.24 | 10.51 | 10.01 | 12.04 | 15.58 | 11.88 | 11.93 | 4.57 | 7.06 | 6.76 | 9.50 | 10.68 | 7.86 | 10.39 | 10.06 | 2.10 | 1.65 | 3.62 | 4.72 |
| — | -20.2% | -53.5% | -11.5% | -16.1% | +163.6% | +120.8% | +75.8% | +25.5% | -57.2% | -10.2% | -35.0% | -5.5% | +409.2% | +376.9% | +187.3% | +113.2% | -65.0% | -76.9% | +22.8% | -6.6% | |
| Interest Coverage | — | — | — | — | — | — | — | — | — | — | — | — | — | — | -11.95 | -19.35 | -1287.50 | — | — | -2568.33 | -1585.89 |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 46 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying PLSE stock.
Pulse Biosciences, Inc.'s current P/E is -49.1x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Pulse Biosciences, Inc.'s current operating margin is -21982.6%. Margins have been expanding over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Pulse Biosciences, Inc.'s business trajectory between earnings reports.